Scott McCallister Named New Chief Medical Officer of Panacos Pharmaceuticals.
Panacos Pharmaceuticals Inc., a biotechnology company developing antiviral therapeutic products, today announced that Scott McCallister, M.D. has joined the company as chief medical officer.
Dr. McCallister will be responsible for medical affairs and will spearhead the company's Phase 3 development efforts for bevirimat, the company's lead candidate in a new class of oral HIV therapeutics called maturation inhibitors, discovered by Panacos scientists and their academic collaborators.
He will report to Graham Allaway, Ph.D., Panacos' president and COO.
Before joining Panacos, Dr. McCallister was director of Virology, Global Medical Affairs for Bristol Myers Squibb Company, where he was responsible for the global medical strategy of the anti-HIV protease inhibitor, atazanavir (REYATAZ), and coordinated the review and approval of other virology studies, both internal and external, at BMS.
Prior to BMS, Dr. McCallister held positions at Boehringer Ingelheim Pharmaceuticals (BI), leading the international clinical development program and regulatory review process for its anti-HIV protease inhibitor, tipranivir (APTIVUS). Also at BI, Dr. McCallister coordinated the design, conduct, and analysis of more than 20 Phase I, II, and III tipranavir development trials, culminating in the FDA and EMEA approval of APTIVUS for the treatment of HIV infection in treatment-experienced patients.
In addition, Dr. McCallister has served as an assistant professor of medicine at Rush Medical College, medical director of the Howard Brown Health Center, and associate chief of HIV Medicine at the Illinois Masonic Medical Center in Chicago, where he established a general HIV clinic, a drop-in sexually transmitted disease clinic, and a women's health clinic for indigent patients. Dr. McCallister completed his studies at St. George's University School of Medicine and the University of California, Los Angeles.
((Comments on this story may be sent to email@example.com))
((Distributed via M2 Communications Ltd - http://www.m2.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Nov 2, 2006|
|Previous Article:||Rodman & Renshaw Forms New Division Focused on Investment Banking Services to the Life Sciences Industry.|
|Next Article:||InterMune, Roche Announce $60 Million Closing of Hepatitis C Program License, Collaboration Agreement.|
|EVOTEC OAI/PANACOS TO DEVELOP ANTI-HIV THERAPIES.|